Advertisement

Interspecies Allometric Scaling

  • Robert P. HunterEmail author
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 199)

Abstract

Lack of approved pharmaceutical agents and very limited pharmacokinetic data in the scientific literature for exotic, wildlife, and zoo species are a major issue for veterinarians treating these species. There are fewer than 15 compounds approved in the United States for zoo and wildlife species compared to nearly 300 drugs licensed for cattle. Zoo veterinarians are therefore required to extrapolate the use of approved agents (veterinary or human) to nonapproved species, often with little or no scientific basis to support drug or dose schedule selection. In general, species differences in drug absorption, metabolism, distribution, and excretion have been well documented for domestic species. However, there has been limited research to provide similar data for nondomestic species. Consequently, with the possible exception of pet bird species, there is little published information on the pharmacokinetic parameters of drugs in nondomestic species. Additionally, because of the commercial value of many zoo species, the traditional method of “trial and error” for drug and dose selection and related compliance issues is often inappropriate. There is an understandable concern, whereby the zoo veterinarian does not wish to be the first to administer an agent or formulation in an untested species. “One medicine” is a central concept in treating zoo species, in that vertebrate species are generally more similar than dissimilar. However, drug absorption can vary within as well as between species. Considering the anatomical differences between true monogastrics (canine and feline species), hind-gut fermentors (rodents, rabbits, horses, and elephants), fore-gut fermentors (Colobus monkeys and kangaroos), and ruminants (cattle, goats, sheep, and antelope), the potential for differences in pharmacokinetic profiles are marked. Moreover, there are potential differences between organisms in a single class. An example is the ability of several snake species to up- and down-regulate their digestive systems. This renders the time course of oral drug absorption dependent on both body temperature and time after feeding. Plasma protein binding may vary considerably between species and may also be temperature dependent. This is very significant when treating poikilothermic (reptiles, amphibians, and fish) species and when conducting pharmacokinetic studies with highly protein-bound drugs. The large body sizes of some zoo species create additional considerations for treatment with drugs and can place significant limitations on delivery of an effective drug dose.

Keywords

Allometric scaling Gastrointestinal Interspecies Intraspecies Pharmacokinetics Zoological pharmacology 

References

  1. Benedict FG (1938) Vital energetics: A study in comparative basal metabolism. Carnegie Institution of Washington, Washington, DCGoogle Scholar
  2. Boxenbaum H, Dilea C (1995) First-time-in-human dose selection: Allometric thoughts and perspectives. J Clin Pharmacol 35:957–966PubMedGoogle Scholar
  3. Boxenbaum H, Fertig JB (1984) Scaling of antipyrine intrinsic clearance of unbound drug on 15 mammalian species. Eur J Drug Metab Pharmacokinet 9:177–183CrossRefPubMedGoogle Scholar
  4. Brodie BB, Reid WD (1967) Some pharmacological consequences of species variation in rates of metabolism. Fed Proc 26:1062–1070PubMedGoogle Scholar
  5. Careau V, Morand-Ferron J, Thomas D (2007) Basal metabolic rate of canidae from hot deserts to cold arctic climates. J Mammal 88:394–400CrossRefGoogle Scholar
  6. Chaui-Berlinck JG (2006) A critical understanding of the fractal model of metabolic scaling. J Exp Biol 209:3045–3054CrossRefPubMedGoogle Scholar
  7. Coke RL (2000) Respiratory biology and diseases of captive lizards (Saurie). Vet Clin North Am Exot Anim Pract 3:531–536PubMedGoogle Scholar
  8. Coke RL, Hunter RP, Isaza R, Koch DE, Goatley MA, Carpenter JW (2003) Pharmacokinetics and tissue concentrations of azithromycin in ball pythons (Python regius). Am J Vet Res 64:225–228CrossRefPubMedGoogle Scholar
  9. Cuthbert R, Pain DJ, Green RE, Swan G, Swarup D (2007) Comparative toxicity studies of NSAIDs in birds: a criticism of Reddy et al. Environ Toxicol Pharm 23:254–255CrossRefGoogle Scholar
  10. Dorrestein GM (2000) Quick reference for drug dosing. In: Tully TN, Lawton MPC, Dorrestein GM (eds) Avian medicine. Butterworth Heinemann, Oxford, UK, pp 386–390CrossRefGoogle Scholar
  11. Downes H (2002) Relative metabolic rate as a basis for extrapolation of drug-elimination times from mammals to frogs. J Herpetol Med Surg 12:4–11Google Scholar
  12. Fowler ME (1995) Restraint and handling of wild and domestic animals, 2nd edn. Iowa State University Press, Ames, IAGoogle Scholar
  13. Frazier DL, Jones MP, Orosz SE (1995) Pharmacokinetic considerations of the renal system in birds: part I. Anatomic and physiologic principles of allometric scaling. J Avian Med Surg 9:92–103Google Scholar
  14. Funk RS (2000) A formulary for lizards, snakes, and crocodilians. Vet Clin North Am Exot Anim Pract 3:333–358PubMedGoogle Scholar
  15. Gamble KC, Jensen JM, Boothe DM, Heatley JJ, Helmick KE (1995) Pharmacokinetics of amikacin in scimitar-horned oryx (Oryx dammah) from a single intravenous dose. J Zoo Wildlife Med 26:359–366Google Scholar
  16. Hunter RP, Isaza R (2008) Concepts and issues with interspecies scaling in zoological medicine. J Zoo Wildlife Med 39:517–526CrossRefGoogle Scholar
  17. Hunter RP, Koch DE, Coke RL, Goatley MA, Isaza R (2003) Azithromycin metabolite identification in plasma, bile and tissues of the ball python (Python regius). J Vet Pharmacol Ther 26:117–121CrossRefPubMedGoogle Scholar
  18. Hunter RP, Mahmood I, Martinez MN (2008) Prediction of xenobiotic clearance in avian species using mammalian data: how accurate is the prediction? J Vet Pharmacol Ther 31:281–284CrossRefPubMedGoogle Scholar
  19. Jacobson ER (1996) Metabolic scaling of antibiotics in reptiles: basis and limitations. Zoo Biol 15:329–339CrossRefGoogle Scholar
  20. Kleiber M (1932) Body size and metabolism. Hilgarida 6:315–353Google Scholar
  21. Kleiber M (1961) The fire of life. An introduction to animal energetics. Wiley, New York, NYGoogle Scholar
  22. Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P (1997) Integration of in vitro data into allometric scaling to predict hepatic metabolic clearance in man: application to 10 extensively metabolized drugs. J Pharm Sci 86:584–590CrossRefPubMedGoogle Scholar
  23. Lees P, AliAbadi FS (2002) Rational dosing of antimicrobial drugs: Animals versus humans. Int J Antimicrobial Agents 19:269–284CrossRefGoogle Scholar
  24. Lepist E-I, Jusko WJ (2004) Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: A retrospective analysis. J Vet Pharmacol Ther 27:211–218CrossRefPubMedGoogle Scholar
  25. Locke D, Bush M, Carpenter JW (1982) Pharmacokinetics and tissue concentrations of tylosin in selected avian species. Am J Vet Res 43:1807–1810PubMedGoogle Scholar
  26. Mahmood I (2005) Interspecies pharmacokinetic scaling: Principles and application of allometric scaling. Pine House, Rockville, MDGoogle Scholar
  27. Mahmood I (2007) Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59:1177–1192CrossRefPubMedGoogle Scholar
  28. Mahmood I, Balian JD (1999) The pharmacokinetic principles behind scaling from preclinical results to phase I protocols. Clin Pharmacokinet 36:1–11CrossRefPubMedGoogle Scholar
  29. Mahmood I, Green MD, Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692–697PubMedGoogle Scholar
  30. Mahmood I, Martinez M, Hunter RP (2006) Interspecies allometric scaling. Part I: prediction of clearance in large animals. J Vet Pharmacol Ther 29:415–423CrossRefPubMedGoogle Scholar
  31. Manire CA, Rhinehart HL, Pennick GJ, Sutton DA, Hunter RP, Rinaldi MG (2003) Steady-state plasma concentrations of itraconazole following oral administration in Kemp’s Ridley sea turtles, Lepidochelys kempi. J Zoo Wildlife Med 34:171–178Google Scholar
  32. Martinez MN (2005) Interspecies differences in physiology and pharmacology: extrapolating preclinical data to human populations. In: Rogge M, Taft D (eds) Preclinical drug development. Marcel Dekker, New York, NY, pp 11–66CrossRefGoogle Scholar
  33. Martinez M, Mahmood I, Hunter RP (2006) Interspecies allometric scaling: prediction of clearance in large animal species: Part II: mathematical considerations. J Vet Pharmacol Ther 29:425–432CrossRefPubMedGoogle Scholar
  34. Martinez M, Mahmood I, Hunter RP (2009) Allometric scaling of clearance in dogs. J Vet Pharmacol Ther 32:411–416CrossRefPubMedGoogle Scholar
  35. Morris TH (1999) Dosage estimation among species. In: Hawk CT, Leary SL (eds) Formulary for laboratory animals, 2nd edn. Iowa State University Press, Ames, IA, pp 3–12Google Scholar
  36. Mortenson J (2001) Determining dosages for antibiotic and anti-inflammatory agents. In: Csuti B, Sargent EL, Bechert US (eds) The elephant’s foot: Prevention and care of foot conditions in captive Asian and African elephants. Iowa State University Press, Ames, IA, pp 141–144Google Scholar
  37. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism. J Pharmacol Exp Ther 283:46–58PubMedGoogle Scholar
  38. Packard GC, Birchard GF (2008) Traditional allometric analysis fails to provide a valid predictive model for mammalian metabolic rates. J Exp Biol 211:3581–3587CrossRefPubMedGoogle Scholar
  39. Page CD, Mautino M, Derendorf HD, Anhalt JP (1991) Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants. J Zoo Wildlife Med 22:409–416Google Scholar
  40. Riviere JE, Martin-Jimenez T, Sundlof SF, Craigmill AL (1997) Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J Vet Pharmacol Ther 20:453–463CrossRefPubMedGoogle Scholar
  41. Rush EM, Hunter RP, Papich M, Calle P, Clippinger T, Raphael B, Cook R (2005) Pharmacokinetics and safety of acyclovir in tragopans (Tragopan sp.). J Avian Med Surg 19:271–276CrossRefGoogle Scholar
  42. Schmidt-Nielsen K (1984) Scaling: why body size is so important? Cambridge University Press, Cambridge, NYGoogle Scholar
  43. Secor SM, Stein ED, Diamond J (1994) Rapid upregulation of snake intestine in response to feeding: a new model of intestinal adaptation. Am J Physiol 266:G695–G705PubMedGoogle Scholar
  44. Sedgwick CJ (1993) Allometric scaling and emergency care: The importance of body size. In: Fowler ME (ed) Zoo and wild animal medicine, 3rd edn. W. B. Saunders, Philadelphia, PA, pp 34–37Google Scholar
  45. Sedgwick CJ, Borkowski R (1996) Allometric scaling: extrapolating treatment regimens for reptiles. In: Mader DR (ed) Reptile medicine and surgery. W. B. Saunders, Philadelphia, PA, pp 235–241Google Scholar
  46. Singer MA (2001) Of mice and men and elephants: metabolic rate sets glomerular filtration rate. Am J Kidney Dis 37:164–178CrossRefPubMedGoogle Scholar
  47. Spector WS (1956) Handbook of biological data. W. B. Saunders, Philadelphia, PA, pp 163–164Google Scholar
  48. Walker CH (1998) Avian forms of cytochrome P450. Comp Biochem Physiol C 121:65–72CrossRefPubMedGoogle Scholar
  49. West LJ, Pierce CM, Thomas WD (1962) Lysergic acid diethylamide: Its effects on a male Asiatic elephant. Science 138:1100–1103CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Elanco Animal Health, a division of Eli LillyGreenfieldUSA

Personalised recommendations